JP Morgan Private Wealth Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $15.5M | Sell |
114,581
-2,142
| -2% | -$293K | 0.04% | 306 |
|
|
2023
Q2 | $16.7M | Sell |
116,723
-48,036
| -29% | -$7.07M | 0.09% | 176 |
|
|
2023
Q1 | $22.9M | Buy |
164,759
+199
| +0.1% | +$26.8K | 0.05% | 289 |
|
|
2022
Q4 | $22.3M | Sell |
164,560
-26,656
| -14% | -$3.34M | 0.05% | 289 |
|
|
2022
Q3 | $21M | Buy |
191,216
+93,781
| +96% | +$11.9M | 0.05% | 279 |
|
|
2022
Q2 | $12.9M | Buy |
97,435
+32,485
| +50% | +$4.26M | 0.03% | 355 |
|
|
2022
Q1 | $8.62M | Buy |
64,950
+2,492
| +4% | +$299K | 0.02% | 476 |
|
|
2021
Q4 | $7.28M | Sell |
62,458
-4,043
| -6% | -$476K | 0.02% | 515 |
|
|
2021
Q3 | $7.99M | Buy |
66,501
+15,948
| +32% | +$1.86M | 0.02% | 476 |
|
|
2021
Q2 | $6.06M | Buy |
50,553
+5,806
| +13% | +$637K | 0.02% | 537 |
|
|
2021
Q1 | $4.45M | Sell |
44,747
-5,800
| -11% | -$583K | 0.01% | 536 |
|
|
2020
Q4 | $5.05M | Buy |
50,547
+2,436
| +5% | +$258K | 0.02% | 482 |
|
|
2020
Q3 | $5.27M | Buy |
48,111
+17,102
| +55% | +$1.9M | 0.02% | 418 |
|
|
2020
Q2 | $3.28M | Buy |
31,009
+8,168
| +36% | +$844K | 0.02% | 461 |
|
|
2020
Q1 | $2.04M | Sell |
22,841
-2,016
| -8% | -$190K | 0.01% | 540 |
|
|
2019
Q4 | $2.48M | Sell |
24,857
-3,272
| -12% | -$308K | 0.01% | 570 |
|
|
2019
Q3 | $2.51M | Sell |
28,129
-151
| -0.5% | -$13.1K | 0.01% | 546 |
|
|
2019
Q2 | $2.33M | Sell |
28,280
-13,750
| -33% | -$1.08M | 0.01% | 561 |
|
|
2019
Q1 | $3.4M | Buy |
42,030
+6,312
| +18% | +$498K | 0.02% | 495 |
|
|
2018
Q4 | $2.71M | Buy |
35,718
+376
| +1% | +$29.4K | 0.02% | 508 |
|
|
2018
Q3 | $2.8M | Sell |
35,342
-859
| -2% | -$65K | 0.01% | 558 |
|
|
2018
Q2 | $2.54M | Buy |
36,201
+6,901
| +24% | +$496K | 0.01% | 550 |
|
|
2018
Q1 | $2.05M | Buy |
29,300
+1,387
| +5% | +$96.1K | 0.01% | 479 |
|
|
2017
Q4 | $1.94M | Buy |
27,913
+3,455
| +14% | +$233K | 0.01% | 492 |
|
|
2017
Q3 | $1.66M | Sell |
24,458
-6,925
| -22% | -$437K | 0.01% | 510 |
|
|
2017
Q2 | $2.14M | Sell |
31,383
-19,821
| -39% | -$1.29M | 0.02% | 444 |
|
|
2017
Q1 | $3.19M | Sell |
51,204
-9,762
| -16% | -$568K | 0.02% | 381 |
|
|
2016
Q4 | $3.33M | Sell |
60,966
-10,618
| -15% | -$603K | 0.03% | 345 |
|
|
2016
Q3 | $4.7M | Sell |
71,584
-113
| -0.2% | -$7.39K | 0.04% | 288 |
|
|
2016
Q2 | $4.33M | Buy |
71,697
+4,231
| +6% | +$246K | 0.04% | 288 |
|
|
2016
Q1 | $3.8M | Buy |
67,466
+8,740
| +15% | +$525K | 0.04% | 292 |
|
|
2015
Q4 | $3.99M | Buy |
58,726
+46,696
| +388% | +$3.06M | 0.04% | 259 |
|
|
2015
Q3 | $766K | Sell |
12,030
-9,222
| -43% | -$607K | 0.01% | 525 |
|
|
2015
Q2 | $1.35M | Buy |
21,252
+8,487
| +66% | +$581K | 0.02% | 438 |
|
|
2015
Q1 | $873K | Sell |
12,765
-103
| -0.8% | -$7.16K | 0.01% | 562 |
|
|
2014
Q4 | $906K | Buy |
12,868
+1,365
| +12% | +$97.7K | 0.01% | 552 |
|
|
2014
Q3 | $822K | Buy |
11,503
+3,852
| +50% | +$282K | 0.01% | 557 |
|
|
2014
Q2 | $569K | Sell |
7,651
-1,620
| -17% | -$117K | 0.01% | 529 |
|
|
2014
Q1 | $602K | Sell |
9,271
-4,041
| -30% | -$261K | 0.01% | 514 |
|
|
2013
Q4 | $790K | Buy |
13,312
+1,776
| +15% | +$96.5K | 0.02% | 387 |
|
|
2013
Q3 | $599K | Sell |
11,536
-16
| -0.1% | -$804 | 0.01% | 402 |
|
|
2013
Q2 | $546K | Buy |
+11,552
| New | +$588K | 0.01% | 400 |
|
Other funds holding AZN
JP Morgan Private Wealth Advisors's AZN Position: Q3 2023 in Review
JP Morgan Private Wealth Advisors reduced its AstraZeneca (AZN) stake by 1.8% in Q3 2023, selling an estimated $293K and leaving 114,581 shares worth $15.5M. The position accounts for 0.04% of the portfolio, ranked #306.
JP Morgan Private Wealth Advisors first reported a position in AZN in Q2 2013 and has held it in 42 quarters since. The position peaked at $22.9M in Q1 2023. 1,075 funds tracked by Wall St. Rank hold AZN as of Q3 2023.
- JP Morgan Private Wealth Advisors held 114,581 shares of AstraZeneca worth $15.5M as of Q3 2023.
- JP Morgan Private Wealth Advisors sold 2,142 AstraZeneca shares in Q3 2023, an estimated $293K.
- AstraZeneca made up 0.04% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #306 holding.
- JP Morgan Private Wealth Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 42 quarters since.
- JP Morgan Private Wealth Advisors's AstraZeneca position peaked at $22.9M in Q1 2023.
- 1,075 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.
Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.